RYTM Relative Valuation
RYTM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RYTM is overvalued; if below, it's undervalued.
Historical Valuation
Rhythm Pharmaceuticals Inc (RYTM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -12.77. The fair price of Rhythm Pharmaceuticals Inc (RYTM) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 105.70 USD , Rhythm Pharmaceuticals Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：105.70
Fair
Undervalued
-34.68
PE
1Y
3Y
5Y
Trailing
Forward
-36.95
EV/EBITDA
Rhythm Pharmaceuticals Inc. (RYTM) has a current EV/EBITDA of -36.95. The 5-year average EV/EBITDA is -10.59. The thresholds are as follows: Strongly Undervalued below -32.35, Undervalued between -32.35 and -21.47, Fairly Valued between 0.29 and -21.47, Overvalued between 0.29 and 11.17, and Strongly Overvalued above 11.17. The current Forward EV/EBITDA of -36.95 falls within the Strongly Undervalued range.
-39.74
EV/EBIT
Rhythm Pharmaceuticals Inc. (RYTM) has a current EV/EBIT of -39.74. The 5-year average EV/EBIT is -11.11. The thresholds are as follows: Strongly Undervalued below -33.08, Undervalued between -33.08 and -22.09, Fairly Valued between -0.12 and -22.09, Overvalued between -0.12 and 10.87, and Strongly Overvalued above 10.87. The current Forward EV/EBIT of -39.74 falls within the Strongly Undervalued range.
27.07
PS
Rhythm Pharmaceuticals Inc. (RYTM) has a current PS of 27.07. The 5-year average PS is 51.06. The thresholds are as follows: Strongly Undervalued below -141.54, Undervalued between -141.54 and -45.24, Fairly Valued between 147.36 and -45.24, Overvalued between 147.36 and 243.66, and Strongly Overvalued above 243.66. The current Forward PS of 27.07 falls within the Historic Trend Line -Fairly Valued range.
-66.12
P/OCF
Rhythm Pharmaceuticals Inc. (RYTM) has a current P/OCF of -66.12. The 5-year average P/OCF is -17.13. The thresholds are as follows: Strongly Undervalued below -54.26, Undervalued between -54.26 and -35.69, Fairly Valued between 1.44 and -35.69, Overvalued between 1.44 and 20.01, and Strongly Overvalued above 20.01. The current Forward P/OCF of -66.12 falls within the Strongly Undervalued range.
-43.48
P/FCF
Rhythm Pharmaceuticals Inc. (RYTM) has a current P/FCF of -43.48. The 5-year average P/FCF is -12.21. The thresholds are as follows: Strongly Undervalued below -34.81, Undervalued between -34.81 and -23.51, Fairly Valued between -0.92 and -23.51, Overvalued between -0.92 and 10.38, and Strongly Overvalued above 10.38. The current Forward P/FCF of -43.48 falls within the Strongly Undervalued range.
Rhythm Pharmaceuticals Inc (RYTM) has a current Price-to-Book (P/B) ratio of 47.36. Compared to its 3-year average P/B ratio of 34.20 , the current P/B ratio is approximately 38.48% higher. Relative to its 5-year average P/B ratio of 21.78, the current P/B ratio is about 117.42% higher. Rhythm Pharmaceuticals Inc (RYTM) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.74%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -14.30% , the current FCF yield is about -100.00% lower.
47.36
P/B
Median3y
34.20
Median5y
21.78
-1.56
FCF Yield
Median3y
-6.74
Median5y
-14.30
Competitors Valuation Multiple
The average P/S ratio for RYTM's competitors is 0.80, providing a benchmark for relative valuation. Rhythm Pharmaceuticals Inc Corp (RYTM) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 54.28%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RYTM increased by 88.82% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -21.82 to -34.03.
The secondary factor is the Revenue Growth, contributed 54.28%to the performance.
Overall, the performance of RYTM in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Rhythm Pharmaceuticals Inc (RYTM) currently overvalued or undervalued?
What is Rhythm Pharmaceuticals Inc (RYTM) fair value?
How does RYTM's valuation metrics compare to the industry average?
What is the current P/B ratio for Rhythm Pharmaceuticals Inc (RYTM) as of Dec 05 2025?
What is the current FCF Yield for Rhythm Pharmaceuticals Inc (RYTM) as of Dec 05 2025?
What is the current Forward P/E ratio for Rhythm Pharmaceuticals Inc (RYTM) as of Dec 05 2025?